Physician profile
Nabil Keith
NPI 1306032198
$7,642.87
in general payments reported to CMS, 2019-2025
50 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $630 · 2021: $823 · 2022: $956 · 2023: $1,034 · 2024: $1,828 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,350.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,324.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $645.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $622.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $533.87 | 2019-2025 | Rexulti |
| Novo Nordisk INC | $476.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $407.79 | 2019-2025 | |
| Lilly USA, LLC | $376.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $298.41 | 2020-2025 | Airsupra, Farxiga |
| Paratek Pharmaceuticals, INC. | $296.63 | 2022-2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $257.69 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.66 | 2019-2024 | Jardiance |
| Lundbeck LLC | $218.42 | 2020-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $173.28 | 2019-2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $144.98 | 2019-2020 | |
| Axsome Therapeutics, INC. | $136.52 | 2023-2025 | Auvelity, Symbravo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.